Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLL

November 26th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

November 24th 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Juno Files for IPO as CAR Therapies Continue to Advance

November 19th 2014

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

Bringing CARs to Market: Novel T-Cell Therapies Make Rapid Progress Despite Challenges

November 18th 2014

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

Dr. Jain on Increased Lymphocytosis Following Treatment With a B-Cell Receptor Inhibitor

November 5th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

TGR-1202 and Ublituximab Show Promise in CLL

November 5th 2014

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

European Commission Approves Ibrutinib for MCL, CLL

October 21st 2014

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

New Strategies Emerge for Managing CLL Patients in Community Settings

October 20th 2014

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.

Infinity Inks Deals to Expand Research Into Duvelisib

September 23rd 2014

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

September 21st 2014

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

September 18th 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Dr. John Byrd Discusses the Treatment Landscape for CLL

September 9th 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising treatment landscape for patients with chronic lymphocytic leukemia.

Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

August 26th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Dr. Flynn on Obinutuzumab for the Treatment of CLL

August 25th 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

FDA Expands Ibrutinib's CLL Approval

July 28th 2014

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.

FDA Approves Idelalisib for CLL, SLL, and Follicular Lymphoma

July 23rd 2014

The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.

CLL Researcher Excited About Outlook for CDK Inhibitors

July 17th 2014

Joseph Flynn, DO, MPH, focuses on the development of novel therapeutics for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in his research at The Ohio State University Comprehensive Cancer Center.

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

July 15th 2014

Jennifer Woyach, MD, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations.

CDK Becomes Hot Target Again: Cell Cycle Inhibitors Compete for Success in Breast Cancer and CLL

July 11th 2014

As gatekeepers of the cell cycle, the cyclin-dependent kinases are often implicated in the progression of cancer and make prime targets for therapy.

Ofatumumab Misses PFS Endpoint in Bulky CLL

June 30th 2014

Ofatumumab (Arzerra) failed to meet its primary endpoint of improvement in progression-free survival (PFS) in a phase III study of the drug versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukemia (CLL),